ln18 Search Results


96
ATCC cell lines ln 18 cells human glioblastoma cell line atcc atcc crl 2610 hek 293 cells human embryonal kidney cells atcc atcc crl 1573 software
Cell Lines Ln 18 Cells Human Glioblastoma Cell Line Atcc Atcc Crl 2610 Hek 293 Cells Human Embryonal Kidney Cells Atcc Atcc Crl 1573 Software, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cell lines ln 18 cells human glioblastoma cell line atcc atcc crl 2610 hek 293 cells human embryonal kidney cells atcc atcc crl 1573 software/product/ATCC
Average 96 stars, based on 1 article reviews
cell lines ln 18 cells human glioblastoma cell line atcc atcc crl 2610 hek 293 cells human embryonal kidney cells atcc atcc crl 1573 software - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier

95
ATCC human glioblastoma derived cell line
Human Glioblastoma Derived Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human glioblastoma derived cell line/product/ATCC
Average 95 stars, based on 1 article reviews
human glioblastoma derived cell line - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier

90
National Centre for Cell Science ln-229, human glioblastoma epithelial cells
Ln 229, Human Glioblastoma Epithelial Cells, supplied by National Centre for Cell Science, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ln-229, human glioblastoma epithelial cells/product/National Centre for Cell Science
Average 90 stars, based on 1 article reviews
ln-229, human glioblastoma epithelial cells - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Genetica Inc ln18 cell line
(A–D) Type-I IFN-dependent expression of human SLFN genes in GBM (A), patient-derived glioma stem cell lines (B), medulloblastoma cell lines (C), and human normal astrocytes SVGp12 (D). Indicated cells were left untreated (UT) or were treated with human IFNα or IFNβ for 6 hours. qRT-PCR analyses of the relative mRNA expression of SLFN5 , SLFN11 , SLFN12 , SLFN13 , and SLFN14 genes are shown. Data are expressed as fold change over untreated controls, and bar graphs represent means ± SEM of three independent experiments for LN18, LN443, SVGp12, and four independent experiments for JK18, JK46, DAOY, <t>D556,</t> LN229 and U87MG. (Und: undetected) (E) Left Panel , Expression of human SLFN proteins in GBM, medulloblastoma cell lines, and normal brain tissue lysates. The cells were lysed and equal amounts of whole cell lysates were resolved by SDS-PAGE. Immunoblots were probed with antibodies against SLFN5, SLFN11, SLFN12L and GAPDH, as indicated. Immunoblot images are representative of five independent experiments for SLFN5, SLFN11 and two independent experiments for SLFN12L. Right panels , bands from five SLFN5, SLFN11, or two SLFN12L independent experiments (including the blots shown) were quantified by densitometry using Image J software and normalized and reported relative to GAPDH.
Ln18 Cell Line, supplied by Genetica Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ln18 cell line/product/Genetica Inc
Average 90 stars, based on 1 article reviews
ln18 cell line - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
InVivos Pte Ltd idh-mutant ln18-luc cells
(A–D) Type-I IFN-dependent expression of human SLFN genes in GBM (A), patient-derived glioma stem cell lines (B), medulloblastoma cell lines (C), and human normal astrocytes SVGp12 (D). Indicated cells were left untreated (UT) or were treated with human IFNα or IFNβ for 6 hours. qRT-PCR analyses of the relative mRNA expression of SLFN5 , SLFN11 , SLFN12 , SLFN13 , and SLFN14 genes are shown. Data are expressed as fold change over untreated controls, and bar graphs represent means ± SEM of three independent experiments for LN18, LN443, SVGp12, and four independent experiments for JK18, JK46, DAOY, <t>D556,</t> LN229 and U87MG. (Und: undetected) (E) Left Panel , Expression of human SLFN proteins in GBM, medulloblastoma cell lines, and normal brain tissue lysates. The cells were lysed and equal amounts of whole cell lysates were resolved by SDS-PAGE. Immunoblots were probed with antibodies against SLFN5, SLFN11, SLFN12L and GAPDH, as indicated. Immunoblot images are representative of five independent experiments for SLFN5, SLFN11 and two independent experiments for SLFN12L. Right panels , bands from five SLFN5, SLFN11, or two SLFN12L independent experiments (including the blots shown) were quantified by densitometry using Image J software and normalized and reported relative to GAPDH.
Idh Mutant Ln18 Luc Cells, supplied by InVivos Pte Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/idh-mutant ln18-luc cells/product/InVivos Pte Ltd
Average 90 stars, based on 1 article reviews
idh-mutant ln18-luc cells - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Institute for Clinical Pharmacodynamics glioma cell line u87mg p53si
(A–D) Type-I IFN-dependent expression of human SLFN genes in GBM (A), patient-derived glioma stem cell lines (B), medulloblastoma cell lines (C), and human normal astrocytes SVGp12 (D). Indicated cells were left untreated (UT) or were treated with human IFNα or IFNβ for 6 hours. qRT-PCR analyses of the relative mRNA expression of SLFN5 , SLFN11 , SLFN12 , SLFN13 , and SLFN14 genes are shown. Data are expressed as fold change over untreated controls, and bar graphs represent means ± SEM of three independent experiments for LN18, LN443, SVGp12, and four independent experiments for JK18, JK46, DAOY, <t>D556,</t> LN229 and U87MG. (Und: undetected) (E) Left Panel , Expression of human SLFN proteins in GBM, medulloblastoma cell lines, and normal brain tissue lysates. The cells were lysed and equal amounts of whole cell lysates were resolved by SDS-PAGE. Immunoblots were probed with antibodies against SLFN5, SLFN11, SLFN12L and GAPDH, as indicated. Immunoblot images are representative of five independent experiments for SLFN5, SLFN11 and two independent experiments for SLFN12L. Right panels , bands from five SLFN5, SLFN11, or two SLFN12L independent experiments (including the blots shown) were quantified by densitometry using Image J software and normalized and reported relative to GAPDH.
Glioma Cell Line U87mg P53si, supplied by Institute for Clinical Pharmacodynamics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/glioma cell line u87mg p53si/product/Institute for Clinical Pharmacodynamics
Average 90 stars, based on 1 article reviews
glioma cell line u87mg p53si - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Peak Serum Inc 5% (only line ln 18) fetal bovine serum (fbs)
Decreased TERT promoter methylation associates with histone marks of active transcription and an active exonic SNP. (A) ChIP‐Bis‐Seq of the TERT promoter using an H3ac antibody shows enrichment of unmethylated DNA in the pulled‐down samples (black) relative to the input (gray) in <t>LN‐18</t> cells. The absence of any bars indicates zero percent methylation. Inclusion criteria for read positions were a greater number of reads in the pull‐down relative to the input and ≥ 10 reads in the pull‐down (mean input coverage was 9 reads; mean pull‐down coverage was 13 reads; P = 0.01 for pull‐down efficiency). (B) Confirmation of long‐range bisulfite conversion PCR enriching for unmethylated or methylated CpGs at the TERT proximal promoter (16 CpGs spanning 5:1295265–1295396; region overlaps with some of the CpGs analyzed in 3A) using unmethylated (gray)‐ or methylated (black)‐specific bisulfite conversion PCR, respectively. PCR products generated a 1448‐bp product including the proximal promoter and the exon 2 SNP analyzed in Panel C. * P ≤ 0.05 (C) Long‐range bisulfite conversion PCR (same PCRs as shown in Panel B) showing representative Sanger sequencing results (upward arrow indicates position of the exon 2 SNP) and graphs of the sequencing results ( n = 2–3 sequenced reactions). ‘Active SNP’ means that the nucleotide at the position of the SNP is the one found in the TERT mRNA transcribed in that cell line. The active SNP was either previously identified in all cell lines or was identified here (Fig. S6). Error bars represent standard error of the mean. * P ≤ 0.01, where statistical analysis was performed using 2‐tailed Student's t ‐test with unequal variance.
5% (Only Line Ln 18) Fetal Bovine Serum (Fbs), supplied by Peak Serum Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/5% (only line ln 18) fetal bovine serum (fbs)/product/Peak Serum Inc
Average 90 stars, based on 1 article reviews
5% (only line ln 18) fetal bovine serum (fbs) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Corning Life Sciences ln18 cell line
Analysis of cell proliferation and invasion in GB cells with RNF123-OV. ( A ) A172, <t>HS683,</t> and LN18 cell lines were stably transfected with empty vector (EV1) or a cDNA encoding Myc- RNF123 (RNF123-OV). RNF123-OV and p50 were assessed by Western blot, and β-actin was used as a loading control. ( B ) Quantification of RNF123 expression by RT-qPCR ( t -test, *** p < 0.001). ( C , D ) Proliferation of LN18 (C) and A172 (D) cell lines with RNF123-OV or the empty vector (EV1) (two-way ANOVA, Bonferroni correction *** p < 0.001). ( E , F ) Colony-forming units LN18 (E) and A172 (F) cell lines stably expressing control empty vector 1 (EV1) or RNF123-OV ( t -test, *** p < 0.001). ( G , H ) Percentage of invasion in LN18 (G) and A172 (H) cell lines stably expressing control (EV1) or RNF123-OV ( t -test, * p < 0.05, ** p < 0.01). ( I ) LN18 cell lines expressing control vector (EV1) or RNF123-OV were analyzed by RNA-sequencing to determine differentially expressed (DE) genes in RNF123-OV cell lines. The image shows a heatmap of the most DE genes (adjusted p < 0.05). ( J ) LN18 (RPPA1) and HS683 (RPPA2) cell lines with RNF123-OV were analyzed by RPPA. The image shows a heatmap of the most DE genes in RNF123-OV cell lines (adjusted p < 0.05). ( K ) Integration of DE genes identified in RPPA1 (LN18), RPPA2 (HS683), and RNA-sequencing in RNF123-OV cell lines that are targets of the NF-κB pathway. ( L ) RT-qPCR for SERPINE1 in A172, HS683, and LN18 cell lines expressing EV1 or RNF123-OV ( t -test, *** p < 0.001). ( M ) Western blot for SerpinE1 in A172, HS683, and LN18 cell lines expressing EV1 or RNF123-OV; low (L) and high (H) exposure times for the same image are shown. ( N ) Correlation analysis of RNF123 and SERPINE1 expression using the TCGA dataset from GB tumors ( n = 145; Spearman’s r = −0.27, p < 0.001). Error bars represent the mean ± SD from n = 3 replicates.
Ln18 Cell Line, supplied by Corning Life Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ln18 cell line/product/Corning Life Sciences
Average 90 stars, based on 1 article reviews
ln18 cell line - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

86
Human Protein Atlas ln 18
Analysis of cell proliferation and invasion in GB cells with RNF123-OV. ( A ) A172, <t>HS683,</t> and LN18 cell lines were stably transfected with empty vector (EV1) or a cDNA encoding Myc- RNF123 (RNF123-OV). RNF123-OV and p50 were assessed by Western blot, and β-actin was used as a loading control. ( B ) Quantification of RNF123 expression by RT-qPCR ( t -test, *** p < 0.001). ( C , D ) Proliferation of LN18 (C) and A172 (D) cell lines with RNF123-OV or the empty vector (EV1) (two-way ANOVA, Bonferroni correction *** p < 0.001). ( E , F ) Colony-forming units LN18 (E) and A172 (F) cell lines stably expressing control empty vector 1 (EV1) or RNF123-OV ( t -test, *** p < 0.001). ( G , H ) Percentage of invasion in LN18 (G) and A172 (H) cell lines stably expressing control (EV1) or RNF123-OV ( t -test, * p < 0.05, ** p < 0.01). ( I ) LN18 cell lines expressing control vector (EV1) or RNF123-OV were analyzed by RNA-sequencing to determine differentially expressed (DE) genes in RNF123-OV cell lines. The image shows a heatmap of the most DE genes (adjusted p < 0.05). ( J ) LN18 (RPPA1) and HS683 (RPPA2) cell lines with RNF123-OV were analyzed by RPPA. The image shows a heatmap of the most DE genes in RNF123-OV cell lines (adjusted p < 0.05). ( K ) Integration of DE genes identified in RPPA1 (LN18), RPPA2 (HS683), and RNA-sequencing in RNF123-OV cell lines that are targets of the NF-κB pathway. ( L ) RT-qPCR for SERPINE1 in A172, HS683, and LN18 cell lines expressing EV1 or RNF123-OV ( t -test, *** p < 0.001). ( M ) Western blot for SerpinE1 in A172, HS683, and LN18 cell lines expressing EV1 or RNF123-OV; low (L) and high (H) exposure times for the same image are shown. ( N ) Correlation analysis of RNF123 and SERPINE1 expression using the TCGA dataset from GB tumors ( n = 145; Spearman’s r = −0.27, p < 0.001). Error bars represent the mean ± SD from n = 3 replicates.
Ln 18, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ln 18/product/Human Protein Atlas
Average 86 stars, based on 1 article reviews
ln 18 - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier


Image Search Results


(A–D) Type-I IFN-dependent expression of human SLFN genes in GBM (A), patient-derived glioma stem cell lines (B), medulloblastoma cell lines (C), and human normal astrocytes SVGp12 (D). Indicated cells were left untreated (UT) or were treated with human IFNα or IFNβ for 6 hours. qRT-PCR analyses of the relative mRNA expression of SLFN5 , SLFN11 , SLFN12 , SLFN13 , and SLFN14 genes are shown. Data are expressed as fold change over untreated controls, and bar graphs represent means ± SEM of three independent experiments for LN18, LN443, SVGp12, and four independent experiments for JK18, JK46, DAOY, D556, LN229 and U87MG. (Und: undetected) (E) Left Panel , Expression of human SLFN proteins in GBM, medulloblastoma cell lines, and normal brain tissue lysates. The cells were lysed and equal amounts of whole cell lysates were resolved by SDS-PAGE. Immunoblots were probed with antibodies against SLFN5, SLFN11, SLFN12L and GAPDH, as indicated. Immunoblot images are representative of five independent experiments for SLFN5, SLFN11 and two independent experiments for SLFN12L. Right panels , bands from five SLFN5, SLFN11, or two SLFN12L independent experiments (including the blots shown) were quantified by densitometry using Image J software and normalized and reported relative to GAPDH.

Journal: Oncogene

Article Title: Human SLFN5 is a Transcriptional Co-repressor of STAT1-Mediated Interferon Responses and Promotes the Malignant Phenotype in Glioblastoma

doi: 10.1038/onc.2017.205

Figure Lengend Snippet: (A–D) Type-I IFN-dependent expression of human SLFN genes in GBM (A), patient-derived glioma stem cell lines (B), medulloblastoma cell lines (C), and human normal astrocytes SVGp12 (D). Indicated cells were left untreated (UT) or were treated with human IFNα or IFNβ for 6 hours. qRT-PCR analyses of the relative mRNA expression of SLFN5 , SLFN11 , SLFN12 , SLFN13 , and SLFN14 genes are shown. Data are expressed as fold change over untreated controls, and bar graphs represent means ± SEM of three independent experiments for LN18, LN443, SVGp12, and four independent experiments for JK18, JK46, DAOY, D556, LN229 and U87MG. (Und: undetected) (E) Left Panel , Expression of human SLFN proteins in GBM, medulloblastoma cell lines, and normal brain tissue lysates. The cells were lysed and equal amounts of whole cell lysates were resolved by SDS-PAGE. Immunoblots were probed with antibodies against SLFN5, SLFN11, SLFN12L and GAPDH, as indicated. Immunoblot images are representative of five independent experiments for SLFN5, SLFN11 and two independent experiments for SLFN12L. Right panels , bands from five SLFN5, SLFN11, or two SLFN12L independent experiments (including the blots shown) were quantified by densitometry using Image J software and normalized and reported relative to GAPDH.

Article Snippet: LN18, LN229, LN443, U87MG, DAOY and D556 cell lines were subjected to short tandem repeat (STR) analysis to ensure genetic stability and authenticated where published reference STR profiles were available (Genetica DNA Laboratories).

Techniques: Expressing, Derivative Assay, Quantitative RT-PCR, SDS Page, Western Blot, Software

Decreased TERT promoter methylation associates with histone marks of active transcription and an active exonic SNP. (A) ChIP‐Bis‐Seq of the TERT promoter using an H3ac antibody shows enrichment of unmethylated DNA in the pulled‐down samples (black) relative to the input (gray) in LN‐18 cells. The absence of any bars indicates zero percent methylation. Inclusion criteria for read positions were a greater number of reads in the pull‐down relative to the input and ≥ 10 reads in the pull‐down (mean input coverage was 9 reads; mean pull‐down coverage was 13 reads; P = 0.01 for pull‐down efficiency). (B) Confirmation of long‐range bisulfite conversion PCR enriching for unmethylated or methylated CpGs at the TERT proximal promoter (16 CpGs spanning 5:1295265–1295396; region overlaps with some of the CpGs analyzed in 3A) using unmethylated (gray)‐ or methylated (black)‐specific bisulfite conversion PCR, respectively. PCR products generated a 1448‐bp product including the proximal promoter and the exon 2 SNP analyzed in Panel C. * P ≤ 0.05 (C) Long‐range bisulfite conversion PCR (same PCRs as shown in Panel B) showing representative Sanger sequencing results (upward arrow indicates position of the exon 2 SNP) and graphs of the sequencing results ( n = 2–3 sequenced reactions). ‘Active SNP’ means that the nucleotide at the position of the SNP is the one found in the TERT mRNA transcribed in that cell line. The active SNP was either previously identified in all cell lines or was identified here (Fig. S6). Error bars represent standard error of the mean. * P ≤ 0.01, where statistical analysis was performed using 2‐tailed Student's t ‐test with unequal variance.

Journal: Molecular Oncology

Article Title: Allele‐specific proximal promoter hypomethylation of the telomerase reverse transcriptase gene ( TERT ) associates with TERT expression in multiple cancers

doi: 10.1002/1878-0261.12786

Figure Lengend Snippet: Decreased TERT promoter methylation associates with histone marks of active transcription and an active exonic SNP. (A) ChIP‐Bis‐Seq of the TERT promoter using an H3ac antibody shows enrichment of unmethylated DNA in the pulled‐down samples (black) relative to the input (gray) in LN‐18 cells. The absence of any bars indicates zero percent methylation. Inclusion criteria for read positions were a greater number of reads in the pull‐down relative to the input and ≥ 10 reads in the pull‐down (mean input coverage was 9 reads; mean pull‐down coverage was 13 reads; P = 0.01 for pull‐down efficiency). (B) Confirmation of long‐range bisulfite conversion PCR enriching for unmethylated or methylated CpGs at the TERT proximal promoter (16 CpGs spanning 5:1295265–1295396; region overlaps with some of the CpGs analyzed in 3A) using unmethylated (gray)‐ or methylated (black)‐specific bisulfite conversion PCR, respectively. PCR products generated a 1448‐bp product including the proximal promoter and the exon 2 SNP analyzed in Panel C. * P ≤ 0.05 (C) Long‐range bisulfite conversion PCR (same PCRs as shown in Panel B) showing representative Sanger sequencing results (upward arrow indicates position of the exon 2 SNP) and graphs of the sequencing results ( n = 2–3 sequenced reactions). ‘Active SNP’ means that the nucleotide at the position of the SNP is the one found in the TERT mRNA transcribed in that cell line. The active SNP was either previously identified in all cell lines or was identified here (Fig. S6). Error bars represent standard error of the mean. * P ≤ 0.01, where statistical analysis was performed using 2‐tailed Student's t ‐test with unequal variance.

Article Snippet: All media were supplemented with 100 μg·mL −1 penicillin and 100 μg·mL −1 streptomycin (Gibco Thermo Fisher Scientific) and 10% (Sigma‐Aldrich, St. Louis, MO, USA) or 5% (only line LN‐18) fetal bovine serum (FBS) (Peak Serum Inc., Wellington, Colorado, US).

Techniques: Methylation, Generated, Sequencing

Analysis of cell proliferation and invasion in GB cells with RNF123-OV. ( A ) A172, HS683, and LN18 cell lines were stably transfected with empty vector (EV1) or a cDNA encoding Myc- RNF123 (RNF123-OV). RNF123-OV and p50 were assessed by Western blot, and β-actin was used as a loading control. ( B ) Quantification of RNF123 expression by RT-qPCR ( t -test, *** p < 0.001). ( C , D ) Proliferation of LN18 (C) and A172 (D) cell lines with RNF123-OV or the empty vector (EV1) (two-way ANOVA, Bonferroni correction *** p < 0.001). ( E , F ) Colony-forming units LN18 (E) and A172 (F) cell lines stably expressing control empty vector 1 (EV1) or RNF123-OV ( t -test, *** p < 0.001). ( G , H ) Percentage of invasion in LN18 (G) and A172 (H) cell lines stably expressing control (EV1) or RNF123-OV ( t -test, * p < 0.05, ** p < 0.01). ( I ) LN18 cell lines expressing control vector (EV1) or RNF123-OV were analyzed by RNA-sequencing to determine differentially expressed (DE) genes in RNF123-OV cell lines. The image shows a heatmap of the most DE genes (adjusted p < 0.05). ( J ) LN18 (RPPA1) and HS683 (RPPA2) cell lines with RNF123-OV were analyzed by RPPA. The image shows a heatmap of the most DE genes in RNF123-OV cell lines (adjusted p < 0.05). ( K ) Integration of DE genes identified in RPPA1 (LN18), RPPA2 (HS683), and RNA-sequencing in RNF123-OV cell lines that are targets of the NF-κB pathway. ( L ) RT-qPCR for SERPINE1 in A172, HS683, and LN18 cell lines expressing EV1 or RNF123-OV ( t -test, *** p < 0.001). ( M ) Western blot for SerpinE1 in A172, HS683, and LN18 cell lines expressing EV1 or RNF123-OV; low (L) and high (H) exposure times for the same image are shown. ( N ) Correlation analysis of RNF123 and SERPINE1 expression using the TCGA dataset from GB tumors ( n = 145; Spearman’s r = −0.27, p < 0.001). Error bars represent the mean ± SD from n = 3 replicates.

Journal: Cancers

Article Title: Downregulation of the Ubiquitin-E3 Ligase RNF123 Promotes Upregulation of the NF-κB1 Target SerpinE1 in Aggressive Glioblastoma Tumors

doi: 10.3390/cancers12051081

Figure Lengend Snippet: Analysis of cell proliferation and invasion in GB cells with RNF123-OV. ( A ) A172, HS683, and LN18 cell lines were stably transfected with empty vector (EV1) or a cDNA encoding Myc- RNF123 (RNF123-OV). RNF123-OV and p50 were assessed by Western blot, and β-actin was used as a loading control. ( B ) Quantification of RNF123 expression by RT-qPCR ( t -test, *** p < 0.001). ( C , D ) Proliferation of LN18 (C) and A172 (D) cell lines with RNF123-OV or the empty vector (EV1) (two-way ANOVA, Bonferroni correction *** p < 0.001). ( E , F ) Colony-forming units LN18 (E) and A172 (F) cell lines stably expressing control empty vector 1 (EV1) or RNF123-OV ( t -test, *** p < 0.001). ( G , H ) Percentage of invasion in LN18 (G) and A172 (H) cell lines stably expressing control (EV1) or RNF123-OV ( t -test, * p < 0.05, ** p < 0.01). ( I ) LN18 cell lines expressing control vector (EV1) or RNF123-OV were analyzed by RNA-sequencing to determine differentially expressed (DE) genes in RNF123-OV cell lines. The image shows a heatmap of the most DE genes (adjusted p < 0.05). ( J ) LN18 (RPPA1) and HS683 (RPPA2) cell lines with RNF123-OV were analyzed by RPPA. The image shows a heatmap of the most DE genes in RNF123-OV cell lines (adjusted p < 0.05). ( K ) Integration of DE genes identified in RPPA1 (LN18), RPPA2 (HS683), and RNA-sequencing in RNF123-OV cell lines that are targets of the NF-κB pathway. ( L ) RT-qPCR for SERPINE1 in A172, HS683, and LN18 cell lines expressing EV1 or RNF123-OV ( t -test, *** p < 0.001). ( M ) Western blot for SerpinE1 in A172, HS683, and LN18 cell lines expressing EV1 or RNF123-OV; low (L) and high (H) exposure times for the same image are shown. ( N ) Correlation analysis of RNF123 and SERPINE1 expression using the TCGA dataset from GB tumors ( n = 145; Spearman’s r = −0.27, p < 0.001). Error bars represent the mean ± SD from n = 3 replicates.

Article Snippet: To establish RNF123 overexpressing clones, LN18, A172, and HS683 cell lines (5 × 10 5 cells in 60 mm dishes) (Corning, NY, USA) were transfected with Myc-tagged RNF123 vector (OriGene, Rockville, MD) using the jetPRIME transfection reagent.

Techniques: Stable Transfection, Transfection, Plasmid Preparation, Western Blot, Control, Expressing, Quantitative RT-PCR, RNA Sequencing

MiR-155-5p decreased RNF123 expression and gave a poor prognosis in GB patients. ( A ) TCGA analysis of a merged cohort of low-grade glioma and GB for copy number variations and mutations. The frequency of RNF123 alteration is 0.8% of a total of 1084 patients. ( B ) Correlation analysis of miR-155-5p and RNF123 expression using TCGA dataset from GB tumors ( n = 145; Pearson r = −0.277, p = 0.0007). ( C ) TCGA database analysis of miR-155 in GB tissue ( n = 202) compared to normal brain tissue ( n = 11) ( t -test, *** p < 0.001). ( D ) Rembrandt database analysis of miR-155 expression in GB tissue ( n = 214) compared to normal brain tissue ( n = 21) ( t -test, *** p < 0.001). ( E ) TCGA database analysis of RNA-sequencing data for miR-155 in IDH WT ( n = 145) or mutated ( n = 8) GB tissue compared to normal brain tissue ( n = 5) (one-way ANOVA, *** p < 0.001, NS = non-significant). ( F ) LN18, A172, and HS683 cell lines were transfected with pre-miR-155-5p (miR-155-5p-OV) or miR control (miR-Ctrl) and RNF123 expression was quantified by Western blot. ( G ) miR-155-5p sequence aligned with human RNF123 WT 3′-UTR (WT) and RNF123 Mutant 3′-UTR (Mut) sequences. ( H ) Luciferase reporter activity assay to determine the effect of miR-155-5p on 3′-UTR of RNF123 using human RNF123 3′-UTR (WT) and RNF123 Mutant 3′-UTR (Mut) sequences cloned in RenSP vector ( t -test, NS = non-significant, *** p < 0.001). ( I ) Percentage of invasion of LN18 cell lines with miR-155-5p-OV, RNF123-OV, or both compared to control cell lines (one-way ANOVA, * p < 0.05, NS = non-significant). ( J ) Correlation analysis of miR-155-5p and SERPINE1 expression using TCGA dataset from GB tumors ( n = 145; Pearson r = 0.368, p < 0.0001). ( K ) GB patients from the TCGA database were split into low ( n = 90) and high ( n = 90) miR-155-5p expression and analyzed for RNF123 expression ( t -test, * p < 0.05). ( L ) Kaplan–Meier curves for the OS of GB patients expressing low ( n = 87) versus high ( n = 87) miR-155-5p (log-rank test, p = 0.024). ( M ) Dot plot to determine miR-155-5p expression in pre-operative plasma from GB patients ( n = 19) and plasma of healthy controls ( n = 46) ( t -test, ** p = 0.024). Error bars represent mean ± SD from replicates ( n = 3).

Journal: Cancers

Article Title: Downregulation of the Ubiquitin-E3 Ligase RNF123 Promotes Upregulation of the NF-κB1 Target SerpinE1 in Aggressive Glioblastoma Tumors

doi: 10.3390/cancers12051081

Figure Lengend Snippet: MiR-155-5p decreased RNF123 expression and gave a poor prognosis in GB patients. ( A ) TCGA analysis of a merged cohort of low-grade glioma and GB for copy number variations and mutations. The frequency of RNF123 alteration is 0.8% of a total of 1084 patients. ( B ) Correlation analysis of miR-155-5p and RNF123 expression using TCGA dataset from GB tumors ( n = 145; Pearson r = −0.277, p = 0.0007). ( C ) TCGA database analysis of miR-155 in GB tissue ( n = 202) compared to normal brain tissue ( n = 11) ( t -test, *** p < 0.001). ( D ) Rembrandt database analysis of miR-155 expression in GB tissue ( n = 214) compared to normal brain tissue ( n = 21) ( t -test, *** p < 0.001). ( E ) TCGA database analysis of RNA-sequencing data for miR-155 in IDH WT ( n = 145) or mutated ( n = 8) GB tissue compared to normal brain tissue ( n = 5) (one-way ANOVA, *** p < 0.001, NS = non-significant). ( F ) LN18, A172, and HS683 cell lines were transfected with pre-miR-155-5p (miR-155-5p-OV) or miR control (miR-Ctrl) and RNF123 expression was quantified by Western blot. ( G ) miR-155-5p sequence aligned with human RNF123 WT 3′-UTR (WT) and RNF123 Mutant 3′-UTR (Mut) sequences. ( H ) Luciferase reporter activity assay to determine the effect of miR-155-5p on 3′-UTR of RNF123 using human RNF123 3′-UTR (WT) and RNF123 Mutant 3′-UTR (Mut) sequences cloned in RenSP vector ( t -test, NS = non-significant, *** p < 0.001). ( I ) Percentage of invasion of LN18 cell lines with miR-155-5p-OV, RNF123-OV, or both compared to control cell lines (one-way ANOVA, * p < 0.05, NS = non-significant). ( J ) Correlation analysis of miR-155-5p and SERPINE1 expression using TCGA dataset from GB tumors ( n = 145; Pearson r = 0.368, p < 0.0001). ( K ) GB patients from the TCGA database were split into low ( n = 90) and high ( n = 90) miR-155-5p expression and analyzed for RNF123 expression ( t -test, * p < 0.05). ( L ) Kaplan–Meier curves for the OS of GB patients expressing low ( n = 87) versus high ( n = 87) miR-155-5p (log-rank test, p = 0.024). ( M ) Dot plot to determine miR-155-5p expression in pre-operative plasma from GB patients ( n = 19) and plasma of healthy controls ( n = 46) ( t -test, ** p = 0.024). Error bars represent mean ± SD from replicates ( n = 3).

Article Snippet: To establish RNF123 overexpressing clones, LN18, A172, and HS683 cell lines (5 × 10 5 cells in 60 mm dishes) (Corning, NY, USA) were transfected with Myc-tagged RNF123 vector (OriGene, Rockville, MD) using the jetPRIME transfection reagent.

Techniques: Expressing, RNA Sequencing, Transfection, Control, Western Blot, Sequencing, Mutagenesis, Luciferase, Activity Assay, Clone Assay, Plasmid Preparation, Clinical Proteomics